On the Record · Elanco Animal Health
Elanco Animal Health acquisitions, on the record
The businesses Elanco Animal Health bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
aqua business, which includes the Clynav productWord for word“In February 2024 we announced the pending sale of our aqua business, which includes the Clynav product, to a subsidiary of Merck Animal Health.” 10-K for 2023 | agreed divestiture | — | — |
Bayer Animal HealthWord for word“In August 2020 we acquired Bayer Animal Health, marking the largest acquisition in industry history.” 10-K for 2023 | acquisition | In August 2020 | — |
KindredBio, Inc. (KindredBio)Word for word“On August 27, 2021, we acquired KindredBio, a publicly traded biopharmaceutical company that developed innovative biologics focused on saving and improving the lives of pets, for aggregate cash purchase consideration of $ 444 million.” 10-K for 2023 | acquisition | On August 27, 2021 | aggregate cash purchase consideration of $ 444 million |
Microbiome R&D platform assets, transferred to BiomEditWord for word“In April 2022, we signed an agreement to transfer assets associated with our microbiome R&D platform to a newly created, independent biopharmaceutical company, BiomEdit, focused on developing solutions for animal and human health.” 10-K for 2023 | agreed divestiture | In April 2022, we signed an agreement | — |
aqua businessWord for word“On July 9, 2024, we closed the sale of our aqua business to a subsidiary of Merck Animal Health, for $1,294 million in cash.” 10-K for 2024 | divestiture | July 9, 2024 | $1,294 million in cash |
manufacturing facility in Speke, U.K. from TriRx Speke LtdWord for word“In November 2024, we acquired a manufacturing facility in Speke, U.K., including its workforce and related assets such as inventory and property and equipment, from a former contract manufacturing supply partner, TriRx Speke Ltd (TriRx Speke), for $36 million.” 10-K for 2024 | acquisition | In November 2024 | $36 million |
NutriQuest, LLCWord for word“In 2023, we acquired certain U.S. marketed products, pipeline products, inventory and an assembled workforce from NutriQuest, LLC (NutriQuest) and certain assets including inventory and distribution rights for certain marketed products from NutriQuest Nutricao Animal Ltda (NutriQuest Brazil).” 10-K for 2024 | acquisition | 2023 | — |
NutriQuest BrazilWord for word“Cash used for investing activities of $169 million during the year ended December 31, 2023, primarily related to $140 million of cash paid for property and equipment and software and $19 million paid for our acquisitions of NutriQuest and NutriQuest Brazil.” 10-K for 2024 | acquisition | 2023 | $19 million paid for our acquisitions of NutriQuest and NutriQuest Brazil |
BiomEdit R&D platformWord for word“an $8 million write-down of the retained equity interest in our previously divested BiomEdit R&D platform (see Note 4. Acquisitions, Divestitures and Other Arrangements to the consolidated financial statements for further information).” 10-K for 2024 | divestiture | — | — |
TriRx Speke manufacturing siteWord for word“In November 2024, we acquired this manufacturing site for approximately $36 million in an effort to minimize supply disruption (see Note 4. Acquisitions and Divestitures to the consolidated financial statements for further information).” 10-K for 2025 | acquisition | In November 2024 | approximately $36 million |
manufacturing facility in Speke, United Kingdom (U.K.) from TriRx Speke LtdWord for word“In November 2024, we acquired a manufacturing facility in Speke, United Kingdom (U.K.), including its workforce and related assets such as inventory and property and equipment (Speke), from a former contract manufacturing supply partner, TriRx Speke Ltd (TriRx Speke).” 10-K for 2025 | acquisition | In November 2024 | — |
Manukau, New Zealand, siteWord for word“Conversely, we may determine it appropriate to divest or close a manufacturing facility, such as the divestiture of our Manukau, New Zealand, site during 2025 or the planned closure of our Kansas City, Kansas, site in 2026.” 10-K for 2025 | divestiture | during 2025 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $45 million | — | — |
| 2017-12-31 | $882.1 million | — | — |
| 2018-12-31 | $0 | — | — |
| 2019-12-31 | $33 million | — | — |
| 2020-12-31 | $5 billion | — | $2.92 billion |
| 2021-12-31 | $342 million | — | $33 million |
| 2022-12-31 | $0 | $0 | $3 million |
| 2023-12-31 | $19 million | $0 | $4 million |
| 2024-12-31 | $41 million | $1.36 billion | — |
| 2025-12-31 | $0 | $9 million | — |
Deal filings since 2016
- 2025-11-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-06-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-08-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-07-09 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2024-07-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-04-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-02-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-08-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-06-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-04-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-08-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-07-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-06-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-08-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-08-03 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2020-06-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-01-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-01-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-12-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-10-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-08-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-04-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-09-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Elanco Animal Health’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.